What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hematological Malignancy (Leukemia- Lymphoma), Neurological Autoimmune Diseases
- Main trialPhase 1/2
- “This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.”In the company’s words, NCT06948981 on ClinicalTrials.gov
Other drugs for Hematological Malignancy (Leukemia- Lymphoma)
- GivinostatItalfarmaco · Phase 3
- QTX-2101Quetzal Therapeutics · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- PelabresibNovartis · Phase 3
Coming up2
- 13 Jan 2028Phase 1 trial completes · ClinicalTrials.gov
- 17 Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 17 Apr 2028 | GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies | |
| Phase 1Recruiting | 13 Jan 2028 | GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026